posted on 2023-03-30, 23:43authored byBarbara Herkert, Audrey Kauffmann, Sandra Mollé, Christian Schnell, Thomas Ferrat, Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux, Eric Billy, David Ruddy, Mark Stump, Daniel Guthy, Mitko Ristov, Keith Calkins, Sauveur-Michel Maira, William R. Sellers, Francesco Hofmann, Michael N. Hall, Saskia M. Brachmann
Concomitant inhibition of PI3Kβ, IGF1R and MAPK signaling are leading to induction of cell death. A) Effects of treatment with the indicated inhibitors as single-agents in RVH-421 were evaluated by immunoblotting using phospho-specific or total target protein antibodies. B) Fractions of living (A-/PI-), necrotic (A-/PI+), early (A+/PI-) and late (A+/PI+) apoptotic cells was measured upon treatment of A101D and C32 with the indicated compounds for 72h. Data are represented as mean ({plus minus}SD) of triplicates. PI3Kβi=rac-KIN-193, PI3Kαi=BYL719, IGF1Ri=AEW541, panPI3Ki=GDC0941, BRAFi=LGX818, MEKi=MEK162